In the validation cohort, the prognostic value of SHI for TTR and OS in HBV-HCC patients was maintained in the AFP-negative group (p = 0.014 and p = 0.020, respectively, Figure 2) and the BCLC 0+A group (p = 0.018 and p = 0.009, respectively, Figure 2). This evidence concerns the gene TTR and hepatocellular carcinoma.